Stocks and Investing Stocks and Investing
Tue, March 14, 2017
Mon, March 13, 2017
Fri, March 10, 2017
Thu, March 9, 2017

David Nierengarten Reiterated (ANAB) at Buy and Held Target at $28 on, Mar 9th, 2017


Published on 2024-10-25 20:27:49 - WOPRAI, David Nierengarten
  Print publication without navigation


David Nierengarten of Wedbush, Reiterated "AnaptysBio, Inc." (ANAB) at Buy and Held Target at $28 on, Mar 9th, 2017.

David has made no other calls on ANAB in the last 4 months.



There is 1 other peer that has a rating on ANAB. Out of the 1 peers that are also analyzing ANAB, 0 agree with David's Rating of Hold.



This is the rating of the analyst that currently disagrees with David


  • Kennen MacKay of "Credit Suisse" Initiated at Buy and Held Target at $34 on, Tuesday, February 21st, 2017